P
Paul H. Hayashi
Researcher at University of North Carolina at Chapel Hill
Publications - 79
Citations - 4777
Paul H. Hayashi is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Liver transplantation & Liver injury. The author has an hindex of 32, co-authored 70 publications receiving 4026 citations. Previous affiliations of Paul H. Hayashi include Duke University & Saint Louis University.
Papers
More filters
Journal ArticleDOI
ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Naga Chalasani,Paul H. Hayashi,Herbert L. Bonkovsky,Victor J. Navarro,William M. Lee,Robert J. Fontana +5 more
TL;DR: This ACG Clinical Guideline is presented an evidence-based approach to diagnosis and management of DILI with special emphasis on DILi due to herbal and dietary supplements and DilI occurring in individuals with underlying liver disease.
Journal ArticleDOI
The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.
TL;DR: One third of patients have fibrosis progression, and one third of these have rapid progression to advanced fibrosis, suggesting nonalcoholic steatohepatitis has a variable histological course.
Journal ArticleDOI
Causality assessment in drug‐induced liver injury using a structured expert opinion process: Comparison to the Roussel‐Uclaf causality assessment method
Don C. Rockey,Leonard B. Seeff,James Rochon,James W. Freston,Naga Chalasani,Maurizio Bonacini,Robert J. Fontana,Paul H. Hayashi +7 more
TL;DR: The structured DILIN expert opinion process produced higher agreement rates and likelihood scores than RUCAM in assessing causality, but there was still considerable interobserver variability in both methods.
Journal ArticleDOI
Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver Injury
Timothy Davern,Naga Chalasani,Robert J. Fontana,Paul H. Hayashi,Petr Protiva,David E. Kleiner,Ronald E. Engle,Hanh Nguyen,Suzanne U. Emerson,Robert H. Purcell,Hans L. Tillmann,Jiezhun Gu,Jose Serrano,Jay H. Hoofnagle +13 more
TL;DR: HEV infection contributes to a small but important proportion of cases of acute liver injury that are suspected to be drug induced, andSerologic testing for HEV infection should be performed, particularly if clinical features are compatible with acute viral hepatitis.
Journal ArticleDOI
A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients
TL;DR: Orlistat is an effective adjunct to dietary weight loss therapy and a potential new treatment option for non‐alcoholic steatohepatitis (NASH).